In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C leads to $15mm for Entellus Medical

Executive Summary

Entellus Medical (minimally invasive treatment for chronic sinusitis) brought in $15mm via a Series C financing led by first-time backer Montagu Newhall Associates, which was joined by returning shareholders Split Rock Partners and SV Life Sciences. The company will use the funds to launch its FinESS sinus technology later this year.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies